Gene transfer is becoming increasingly important as a research tool and has clinical potential as well. The Gene Transfer Vector Core (GTVC) brings expertise to cancer from gene transfer experience in multiple other areas of biomedicine. The interaction with multiple investigators from various disciplines and experience with multiple different types of tissues allows for cross-fertilization of ideas, technical advancements, and innovations in vector technologies. The GTVC provides 1) Consultation with the Principal Investigator 2) Development of novel vectors 3) Purified and concentrated preparations of recombinant adenovirus, adeno-associated virus (AAV), and retrovirus (including lentivirus) 4) Collaborative testing of vectors generated for function and purity, and finally routine preparation 5) Standard cell lines, expression plasmids, and stocks of recombinant reporter viruses GTVC staff and investigators are in close contact through all phases of vector design and generation. Thus, the GTVC serves as both a research and development facility for gene transfer studies, and a service facility for routine vector preparations

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA086862-10
Application #
7900760
Study Section
Subcommittee G - Education (NCI)
Project Start
2009-07-01
Project End
2010-06-30
Budget Start
2009-07-01
Budget End
2010-06-30
Support Year
10
Fiscal Year
2009
Total Cost
$121,270
Indirect Cost
Name
University of Iowa
Department
Type
DUNS #
062761671
City
Iowa City
State
IA
Country
United States
Zip Code
52242
Vijapura, Charmi; Yang, Limin; Xiong, Jinhu et al. (2018) Imaging Features of Nonmalignant and Malignant Architectural Distortion Detected by Tomosynthesis. AJR Am J Roentgenol 211:1397-1404
Brooks, Nathan A; Boland, Riley S; Strigenz, Michael E et al. (2018) Nongenitourinary complications associated with robot-assisted laparoscopic and radical retropubic prostatectomy: A single institution assessment of 1,100 patients over 11 years. Urol Oncol 36:501.e9-501.e13
Sandgren, Jeremy A; Deng, Guorui; Linggonegoro, Danny W et al. (2018) Arginine vasopressin infusion is sufficient to model clinical features of preeclampsia in mice. JCI Insight 3:
Jiang, Cheng-Fei; Shi, Zhu-Mei; Li, Dong-Mei et al. (2018) Estrogen-induced miR-196a elevation promotes tumor growth and metastasis via targeting SPRED1 in breast cancer. Mol Cancer 17:83
Moss, Jennifer L; Xiao, Qian; Matthews, Charles E (2018) Patterns of cancer-related health behaviors among middle-aged and older adults: Individual- and area-level socioeconomic disparities. Prev Med 115:31-38
Monga, Varun; Maliske, Seth M; Kaleem, Hassan et al. (2018) Discrepancy between treatment goals documentation by oncologists and their understanding among cancer patients under active treatment with chemotherapy. Eur J Cancer Care (Engl) :e12973
Swami, Umang; Lenert, Petar; Furqan, Muhammad et al. (2018) Atezolizumab after Nivolumab-Induced Inflammatory Polyarthritis: Can Anti-PD-L1 Immunotherapy Be Administered after Anti-PD-1-Related Immune Toxicities? J Thorac Oncol 13:e102-e103
Seaman, Aaron T; Dukes, Kimberly; Hoffman, Richard M et al. (2018) The complicated 'Yes': Decision-making processes and receptivity to lung cancer screening among head and neck cancer survivors. Patient Educ Couns 101:1741-1747
Shields, Anthony F; Jacobs, Paula M; Sznol, Mario et al. (2018) Immune Modulation Therapy and Imaging: Workshop Report. J Nucl Med 59:410-417
Alexander, Matthew S; Wilkes, Justin G; Schroeder, Samuel R et al. (2018) Pharmacologic Ascorbate Reduces Radiation-Induced Normal Tissue Toxicity and Enhances Tumor Radiosensitization in Pancreatic Cancer. Cancer Res 78:6838-6851

Showing the most recent 10 out of 1080 publications